Graves' Disease Remission Study: MycoMeth Combo
Recruiting
Phase 2
Phase 3
Interventional Study
Graves' Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 205 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- 1. aged 18 to 60 years.
2\. Patients newly diagnosed with Graves' disease.
Exclusion Criteria:
* 1\. Patients with Graves' disease who have undergone treatment or experienced relapse.
2\. Hyperthyroidism due to other etiologies (toxic multinodular goiter, toxic thyroid …
Contacts